Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry

Ann Marie Navar; Eric D. Peterson; Shuang Li; Jennifer G. Robinson; Veronique L. Roger; Anne C. Goldberg; Salim Virani; Peter W.F. Wilson; Michael G. Nanna; L. Veronica Lee; Joseph Elassal; Tracy Y. Wang

doi:10.1161/CIRCOUTCOMES.117.004249

Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry

Ann Marie Navar, Eric D. Peterson, Shuang Li, Jennifer G. Robinson, Veronique L. Roger, Anne C. Goldberg, Salim Virani, Peter W.F. Wilson, Michael G. Nanna, L. Veronica Lee, Joseph Elassal, Tracy Y. Wang

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Original language	English
Article number	e004249
Journal	Circulation: Cardiovascular Quality and Outcomes
Volume	11
Issue number	3
DOIs	https://doi.org/10.1161/CIRCOUTCOMES.117.004249
State	Published - Mar 1 2018

Keywords

Cardiovascular disease
Drug-related side effects and adverse reactions
Hydroxymethylglutaryl-CoA reductase inhibitors
Nocebo effect

Access to Document

10.1161/CIRCOUTCOMES.117.004249

Cite this

Navar, A. M., Peterson, E. D., Li, S., Robinson, J. G., Roger, V. L., Goldberg, A. C., Virani, S., Wilson, P. W. F., Nanna, M. G., Lee, L. V., Elassal, J., & Wang, T. Y. (2018). Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry. Circulation: Cardiovascular Quality and Outcomes, 11(3), Article e004249. https://doi.org/10.1161/CIRCOUTCOMES.117.004249

@article{d29c6fdf763a4910aac2d71967beb842,

title = "Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry",

keywords = "Cardiovascular disease, Drug-related side effects and adverse reactions, Hydroxymethylglutaryl-CoA reductase inhibitors, Nocebo effect",

author = "Navar, {Ann Marie} and Peterson, {Eric D.} and Shuang Li and Robinson, {Jennifer G.} and Roger, {Veronique L.} and Goldberg, {Anne C.} and Salim Virani and Wilson, {Peter W.F.} and Nanna, {Michael G.} and Lee, {L. Veronica} and Joseph Elassal and Wang, {Tracy Y.}",

note = "Funding Information: Dr Navar reports research support from Regeneron/Sanofi, Amgen, and Janssen Pharmaceuticals; acts as a consultant for Sanofi and Amgen; and also funded by National Institutes of Health (NIH) K01HL133416-01. Dr Peterson reports research support from Eli Lilly, Janssen, and Merck; and acts as a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, and Sanofi Aventis. Dr Robinson reports re- search support from Amarin, Amgen, AstraZeneca, Eli Lilly, Esai, Glaxo-Smith Kline, Merck, Pfizer, Regeneron/Sanofi, and Takeda; and acts as a consultant for Amgen, Eli Lilly, Merck, Pfizer, and Regeneron/Sanofi. Dr Goldberg reports research support from Amarin, Amgen, Pfizer, Merck, Regeneron/ Sanofi, IONIS, Genzyme/Isis, and Regeneron; acts as a consultant for Optum Rx, Regeneron/Sanofi, and Esperion; and receives honorarium for editorial work Merck Manual. Dr Vi-rani reports research support from American Diabetes Association/American Heart Association/Veterans Affairs; receives honorarium from American College of Cardiology as the Associate Editor for Innovations, ACC.org; none of these are related to the topic of this work. Dr Lee reports employment with Sanofi. Dr Elassal reports employment with Regeneron. Dr Wang reports research support from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Glaxo SmithKline, Regeneron, and Sanofi; and acts as a consultant/advisory/education from Bristol Myers Squibb, Astra Zeneca, Ali Lilly, and Premier, Inc. The other authors report no conflicts. Funding Information: This study was supported by Sanofi Pharmaceuticals and Re-generon Pharmaceuticals.",

year = "2018",

month = mar,

day = "1",

doi = "10.1161/CIRCOUTCOMES.117.004249",

language = "English",

volume = "11",

journal = "Circulation: Cardiovascular Quality and Outcomes",

issn = "1941-7713",

number = "3",

}

Navar, AM, Peterson, ED, Li, S, Robinson, JG, Roger, VL, Goldberg, AC, Virani, S, Wilson, PWF, Nanna, MG, Lee, LV, Elassal, J & Wang, TY 2018, 'Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry', Circulation: Cardiovascular Quality and Outcomes, vol. 11, no. 3, e004249. https://doi.org/10.1161/CIRCOUTCOMES.117.004249

Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry. / Navar, Ann Marie; Peterson, Eric D.; Li, Shuang et al.
In: Circulation: Cardiovascular Quality and Outcomes, Vol. 11, No. 3, e004249, 01.03.2018.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry

AU - Navar, Ann Marie

AU - Peterson, Eric D.

AU - Li, Shuang

AU - Robinson, Jennifer G.

AU - Roger, Veronique L.

AU - Goldberg, Anne C.

AU - Virani, Salim

AU - Wilson, Peter W.F.

AU - Nanna, Michael G.

AU - Lee, L. Veronica

AU - Elassal, Joseph

AU - Wang, Tracy Y.

N1 - Funding Information: Dr Navar reports research support from Regeneron/Sanofi, Amgen, and Janssen Pharmaceuticals; acts as a consultant for Sanofi and Amgen; and also funded by National Institutes of Health (NIH) K01HL133416-01. Dr Peterson reports research support from Eli Lilly, Janssen, and Merck; and acts as a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, and Sanofi Aventis. Dr Robinson reports re- search support from Amarin, Amgen, AstraZeneca, Eli Lilly, Esai, Glaxo-Smith Kline, Merck, Pfizer, Regeneron/Sanofi, and Takeda; and acts as a consultant for Amgen, Eli Lilly, Merck, Pfizer, and Regeneron/Sanofi. Dr Goldberg reports research support from Amarin, Amgen, Pfizer, Merck, Regeneron/ Sanofi, IONIS, Genzyme/Isis, and Regeneron; acts as a consultant for Optum Rx, Regeneron/Sanofi, and Esperion; and receives honorarium for editorial work Merck Manual. Dr Vi-rani reports research support from American Diabetes Association/American Heart Association/Veterans Affairs; receives honorarium from American College of Cardiology as the Associate Editor for Innovations, ACC.org; none of these are related to the topic of this work. Dr Lee reports employment with Sanofi. Dr Elassal reports employment with Regeneron. Dr Wang reports research support from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Glaxo SmithKline, Regeneron, and Sanofi; and acts as a consultant/advisory/education from Bristol Myers Squibb, Astra Zeneca, Ali Lilly, and Premier, Inc. The other authors report no conflicts. Funding Information: This study was supported by Sanofi Pharmaceuticals and Re-generon Pharmaceuticals.

PY - 2018/3/1

Y1 - 2018/3/1

KW - Cardiovascular disease

KW - Drug-related side effects and adverse reactions

KW - Hydroxymethylglutaryl-CoA reductase inhibitors

KW - Nocebo effect

UR - http://www.scopus.com/inward/record.url?scp=85053398256&partnerID=8YFLogxK

U2 - 10.1161/CIRCOUTCOMES.117.004249

DO - 10.1161/CIRCOUTCOMES.117.004249

M3 - Article

C2 - 29545393

AN - SCOPUS:85053398256

SN - 1941-7713

VL - 11

JO - Circulation: Cardiovascular Quality and Outcomes

JF - Circulation: Cardiovascular Quality and Outcomes

IS - 3

M1 - e004249

ER -

Prevalence and management of symptoms associated with statin therapy in community practice insights from the PALM (patient and provider assessment of lipid management) registry

Keywords

Access to Document

Other files and links

Cite this